Texas Permanent School Fund Corp Acquires 12,249 Shares of TransMedics Group, Inc. $TMDX

Texas Permanent School Fund Corp increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 124.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,118 shares of the company’s stock after buying an additional 12,249 shares during the quarter. Texas Permanent School Fund Corp’s holdings in TransMedics Group were worth $2,964,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Osaic Holdings Inc. grew its position in shares of TransMedics Group by 48.5% during the 2nd quarter. Osaic Holdings Inc. now owns 21,116 shares of the company’s stock valued at $2,830,000 after acquiring an additional 6,899 shares during the period. Thrivent Financial for Lutherans lifted its position in TransMedics Group by 0.9% during the second quarter. Thrivent Financial for Lutherans now owns 24,879 shares of the company’s stock valued at $3,334,000 after purchasing an additional 227 shares in the last quarter. State of Wyoming bought a new stake in TransMedics Group during the second quarter valued at about $76,000. Caxton Associates LLP purchased a new stake in TransMedics Group in the second quarter worth about $242,000. Finally, Public Sector Pension Investment Board raised its stake in shares of TransMedics Group by 8.3% in the second quarter. Public Sector Pension Investment Board now owns 115,335 shares of the company’s stock worth $15,456,000 after buying an additional 8,855 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TMDX. Piper Sandler cut their price objective on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a research note on Thursday, October 30th. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Morgan Stanley raised their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Evercore ISI started coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price on the stock. Finally, Jefferies Financial Group initiated coverage on TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $127.67 on Friday. The firm has a market cap of $4.36 billion, a PE ratio of 51.69 and a beta of 2.06. The stock has a 50 day moving average of $127.74 and a 200 day moving average of $123.00. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 EPS. On average, research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 13,062 shares of company stock worth $1,797,634 in the last ninety days. Company insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.